Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1
about
sameAs
Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutationsSubthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injuryAlterations to myofibrillar protein function in nonischemic regions of the heart early after myocardial infarction.Comparative proteomics analysis of differentially expressed phosphoproteins in adult rat ventricular myocytes subjected to diazoxide preconditioning.Differential proteomic profiling to study the mechanism of cardiac pharmacological preconditioning by resveratrol.ATP-sensitive K+ channel knockout induces cardiac proteome remodeling predictive of heart disease susceptibility.Transmural heterogeneity of cellular level power output is reduced in human heart failure.Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in phosphatase subunit distributionGenome informatics: current status and future prospects.Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2.Functional proteomics to study protection of the ischaemic myocardium.Proteomics and heart disease: identifying biomarkers of clinical utility.A proteomic primer for the clinicianCardiovascular proteomics: past, present, and future.Proteomic technologies in the study of kinases: novel tools for the investigation of PKC in the heart.O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function.Comprehensive analysis of tropomyosin isoforms in skeletal muscles by top-down proteomics.The role of proteomics in clinical cardiovascular biomarker discovery.Proteomic profiling of KATP channel-deficient hypertensive heart maps risk for maladaptive cardiomyopathic outcome.Effects of contractile protein phosphorylation on force development in permeabilized rat cardiac myocytes.Intracellular regulation of matrix metalloproteinase-2 activity: new strategies in treatment and protection of heart subjected to oxidative stressCardiac proteomic responses to ischemia-reperfusion injury and ischemic preconditioning.Variations in apparent mass of mammalian fast-type myosin light chains correlate with species body size, from shrew to elephant.Synergistic protection of MLC 1 against cardiac ischemia/reperfusion-induced degradation: a novel therapeutic concept for the future.Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart.Accessibility of myofilament cysteines and effects on ATPase depend on the activation state during exposure to oxidants.Myosin light chain phosphorylation, novel targets to repair a broken heart?Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts.Myocardial subproteomic analysis of a constitutively active Rac1-expressing transgenic mouse with lethal myocardial hypertrophy.Complete Characterization of Cardiac Myosin Heavy Chain (223 kDa) Enabled by Size-Exclusion Chromatography and Middle-Down Mass Spectrometry.Distinct sequences and post-translational modifications in cardiac atrial and ventricular myosin light chains revealed by top-down mass spectrometry.Differences in Contractile Function of Myofibrils within Human Embryonic Stem Cell-Derived Cardiomyocytes vs. Adult Ventricular Myofibrils Are Related to Distinct Sarcomeric Protein Isoforms.First profiling of lysine crotonylation of myofilament proteins and ribosomal proteins in zebrafish embryos.Essential light chain S195 phosphorylation is required for cardiac adaptation under physical stress.
P2860
Q28088824-ABD7FF0F-2E63-4300-9EC5-D1ADF43E9D7CQ28468522-0347F40C-20ED-4A93-81DC-95B9F0B393A2Q30443317-179FDE97-5577-4270-9D50-0B91B0E64F7CQ33250180-D9666488-1863-46F2-8CA6-E52791943078Q33264601-2558438A-0579-4540-A1E0-8C5BAE5195E3Q33638630-F588BDDA-0A51-4503-BB2B-60E0E6C47DE1Q33680561-95CF5434-AA3A-4E6C-87A5-6F0533A69890Q33770141-BC2B2CF9-F5AE-44FF-95BB-5C5D665B2461Q34049499-06115531-DEAF-441D-BCDE-404DE4576809Q34260616-24B37D1B-7B12-4126-9F5B-FB2D95290B30Q34974770-1CD540F0-6F39-4435-A69A-A447C5A57079Q36445586-AB7BAC2A-8354-4CC1-B22A-F26E283198EBQ36698789-C1F134BB-63B9-4EE5-962A-690174A01444Q36775610-3A06661D-6378-4BC6-A481-5608555CE22AQ36840300-BCF2EA92-D890-404E-8BEE-C04600FEDB51Q37040657-E1053122-810A-463D-9EB6-B1F8C5B95094Q37114271-56F98AD0-908A-498A-BCE4-8174651AA1E3Q37230702-3A3C7D5F-70F8-4F21-AD33-6BF6523D41CBQ37345465-912FEF66-B7C6-461F-B9A4-98EB6B60ADBCQ37428711-4AD4B599-DA97-449E-8B8B-A1644ECBB96AQ37456901-CBB52374-2C6A-4B0D-94EA-032965BC4378Q37866315-C7AC3F5E-F546-40D7-B276-CE2CFF86D012Q38701045-B04DEB89-FD86-4C00-B00E-FED4A414A0F3Q39451153-1344FF48-0DE8-4A76-9851-C10449C78E99Q42058629-8867ED68-0359-42FA-9D72-1C7068D4DA2FQ42442183-DD2E7BA9-0668-4720-9E2C-6141A89472D8Q42707026-83BEB72D-F9D3-46D4-9C6E-9CFED1B104F2Q44758282-00E44ABA-BD96-46D9-B228-279E8A440674Q46697038-D5DB27AC-85F4-4E29-9C2D-16C7520E9648Q47224273-924C0710-6BDB-45AB-A11B-57C12F1B93C4Q48612322-7A4665FE-BA24-490E-8B47-57D8571D613BQ49185907-C58ECF6D-4676-41C7-9642-7ABC7DCCBBCEQ50354214-D9D7ACDB-B022-4B0C-9F92-76546FACE8F5Q53139214-6EE17F8A-62F6-44D0-A9CD-40CDBB6BF8B3
P2860
Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1
description
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im September 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 14 September 2001)
@en
vedecký článok (publikovaný 2001/09/14)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/09/14)
@nl
наукова стаття, опублікована у вересні 2001
@uk
مقالة علمية (نشرت في 14-9-2001)
@ar
name
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@ast
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@en
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@nl
type
label
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@ast
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@en
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@nl
prefLabel
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@ast
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@en
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@nl
P2093
P356
P1433
P1476
Proteomic analysis of pharmaco ...... lation of myosin light chain 1
@en
P2093
P356
10.1161/HH1801.097240
P407
P577
2001-09-14T00:00:00Z